|
Fig. 11 Mulberroside C (MC) promotes white blood cell (WBC) differentiation by activating the RASGRP1/RAS/ERK signaling pathway. (A–G) The expression levels of RASGRP1, RAS, ERK, PU.1, c-FOS, CEBPA, and RUNX1 were assessed by Western blotting after treatment of NB4 cells with MC (5–20 μM). n = 3. (H) Western blot analysis to evaluate the expression of RASGRP1, RAS, ERK, CEBPA, and RUNX1 in NB4 cells treated with MC (20 μM), Q5VWK5 (IL-23R inhibitor, 6.7 μM), or a combination of MC (20 μM) + Q5VWK5 (6.7 μM) for 5 days. The histogram shows the expression levels of RASGRP1, RAS, ERK, CEBPA, and RUNX1 in each treatment group. n = 3. Data are expressed as the mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001 versus corresponding control groups. ns = no significance.